<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03444454</url>
  </required_header>
  <id_info>
    <org_study_id>FdG_VRRS_MS_01</org_study_id>
    <nct_id>NCT03444454</nct_id>
  </id_info>
  <brief_title>Telerehabilitation in Multiple Sclerosis</brief_title>
  <official_title>The Italian Network of Telerehabilitation: Evaluation of Telerehabilitation System for Continuum of Care in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Don Carlo Gnocchi Onlus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IRCCS Centro Neurolesi Bonino-Pulejo, Messina (IT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Fondazione Istituto Neurologico Casimiro Mondino, Pavia (IT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS San Camillo, Venezia, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS San Raffaele Roma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituti Clinici Scientifici Maugeri SpA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Don Carlo Gnocchi Onlus</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the study is to evaluate the efficacy of the Virtual Reality Rehabilitation&#xD;
      System (VRRS, Khymeia) compared to usual care treatment for patients with MS at home.&#xD;
&#xD;
      The effects of the intervention on outcome variables will be assessed using a randomized&#xD;
      controlled trial design with a comparison group receiving usual care training. The&#xD;
      investigators will assess the effect of VRRS system on the quality of life, motor, and&#xD;
      cognitive abilities. (Phase I) In the second phase of the present study we aim to evaluate&#xD;
      the effects induced by the treatment of active (anodal) transcranial Direct Current&#xD;
      Stimulation (tDCS) applied to the left dorsolateral prefrontal cortex (lDLPFC) combined with&#xD;
      VRRS compared to placebo tDCS stimulation combined with VRRS. The effects of the intervention&#xD;
      patient-relevant outcomes will be assessed using a randomized controlled trial design with&#xD;
      four groups. The investigators will assess the effect of VRRS system on patient-relevant&#xD;
      outcomes motor, cognitive and participation. (Phase II)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in measure of quality of life</measure>
    <time_frame>Baseline up to 6 weeks and 6 months</time_frame>
    <description>Quality of life will be measured by 54-item Multiple Sclerosis Quality of Life (MSQOL-54) questionnaire&#xD;
There is no single overall score for the MSQOL-54. Two summary scores - physical health and mental health - can be derived from a weighted combination of scale scores. In addition, there are 12 subscales: physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. There are also two single-item measures: satisfaction with sexual function and change in health.&#xD;
Administration forms and scoring instructions can be downloaded (https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/MSQOL54_995.pdf ).&#xD;
Higher values represent a better outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in balance</measure>
    <time_frame>Baseline up to 6 weeks and 6 months</time_frame>
    <description>Mini-Balance Evalutation System (mini-BES) Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gait</measure>
    <time_frame>Baseline up to 6 weeks and 6 months</time_frame>
    <description>12-item Multiple Sclerosis Walking Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change gross manual dexterity</measure>
    <time_frame>Baseline up to 6 weeks and 6 months</time_frame>
    <description>Box and Block Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in global cognitive status</measure>
    <time_frame>Baseline up to 6 weeks and 6 months</time_frame>
    <description>Montreal Cognitive Assessment (MoCA) test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change cognitive status</measure>
    <time_frame>Baseline up to 6 weeks and 6 months</time_frame>
    <description>Symbol Digit Modalities Test (Form Brief Repeatable Battery of Neuropsychological Tests )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatigue</measure>
    <time_frame>Baseline up to 6 weeks and 6 months</time_frame>
    <description>Fatigue Severity Scale&#xD;
A questionnaire with 9 items (questions)&#xD;
Grading of each FSS item ranges from 1 to 7, where 1 indicates strong disagreement and 7 strong agreement, and the final score represents the mean value of the 9 items&#xD;
Higher values represent a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Emotional Traits</measure>
    <time_frame>Baseline up to 6 weeks and 6 months</time_frame>
    <description>The Regulatory Emotional Self-Efficacy (RESE) scale&#xD;
The RESE scale assesses self-efficacy in expressing positive emotions and self-efficacy in managing negative emotions.&#xD;
With this scale, participants rate (ranging from 1 [not well at all] to 5 [very well]) their capability to manage their emotional life. RESE scale consists of 12 items and are calculated 3 scores: 1) self-efficacy in expressing positive emotions (POS) score; 2)self-efficacy in managing negative emotions (NEG) score; 3)self-efficacy in managing despondency/distress (DES) score&#xD;
Higher values within each score represent a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Behavioral (depression)</measure>
    <time_frame>Baseline up to 6 weeks and 6 months</time_frame>
    <description>Beck Depression Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Behavioral (anxiety)</measure>
    <time_frame>Baseline up to 6 weeks and 6 months</time_frame>
    <description>State-trait anxiety inventory</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>VRRS Khymeia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The group will receive a kit home-based (a tablet home, an exercise equipment, access to a daily individualized training program).&#xD;
The exercise program will be remotely charged by therapist on the patient's computer.&#xD;
Each patient's performed session will be reviewed remotely by the therapist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care program</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VRRS Khymeia plus active tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The group will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VRRS Khymeia plus placebo tDCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The group will receive 5 sessions of an individualized home-based VRRS training combined with placebo tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>VRRS Khymeia</intervention_name>
    <description>Participants will receive an individualized exercise program set up by the therapist. The intervention applied to the experimental group will consist of 30 sessions of Khymeia VRRS training distributed in five sessions for week, each lasting 45 minutes.&#xD;
Each session is constructed by alternating physical with cognitive activities. The sessions will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.</description>
    <arm_group_label>VRRS Khymeia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual care program</intervention_name>
    <description>The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.</description>
    <arm_group_label>Usual care program</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>VRRS Khymeia plus active tDCS</intervention_name>
    <description>Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.&#xD;
The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.</description>
    <arm_group_label>VRRS Khymeia plus active tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>VRRS Khymeia plus placebo tDCS</intervention_name>
    <description>Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training.&#xD;
The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.</description>
    <arm_group_label>VRRS Khymeia plus placebo tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of Multiple Sclerosis (RR and SP) based on McDonald criteria&#xD;
&#xD;
          -  Education â‰¥ 8 ages&#xD;
&#xD;
          -  Italian mother language&#xD;
&#xD;
          -  Right-handedness&#xD;
&#xD;
          -  Use of corticosteroids for three months prior to the study, having and no acute&#xD;
             exacerbations of symptoms within three months of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Existence of visual acuity and acoustic perception problems, to prevent performance of&#xD;
             VRRS activities&#xD;
&#xD;
          -  Relapses next to the time of enrolment (3 months)&#xD;
&#xD;
          -  EDSS &gt; 6.5.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francesca Baglio, MD</last_name>
    <phone>0240308069</phone>
    <email>fbaglio@dongnocchi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Mendozzi, MD</last_name>
    <phone>0240308206</phone>
    <email>lmendozzi@dongnocchi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Irccs Fondazione Don Carlo Gnocchi</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20148</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Mendozzi, MD</last_name>
      <phone>0240308069</phone>
      <email>lmendozzi@dongnocchi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Di Tella S, Pagliari C, Blasi V, Mendozzi L, Rovaris M, Baglio F. Integrated telerehabilitation approach in multiple sclerosis: A systematic review and meta-analysis. J Telemed Telecare. 2020 Aug-Sep;26(7-8):385-399. doi: 10.1177/1357633X19850381. Epub 2019 May 27.</citation>
    <PMID>31132909</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione Don Carlo Gnocchi Onlus</investigator_affiliation>
    <investigator_full_name>Francesca Baglio</investigator_full_name>
    <investigator_title>MD, researcher</investigator_title>
  </responsible_party>
  <keyword>Telerehabilitation</keyword>
  <keyword>Virtual reality</keyword>
  <keyword>Quality of life</keyword>
  <keyword>transcranial Direct Current Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

